Position in ANAB
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$1,445,242
-$1,357,537 QoQ
Shares Held
21,411
-71.8% QoQ
Ownership
0.074%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
#81
of 211 holders
Holding Since
Dec 2023
10 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ANAB Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026XTX Topco Ltd holds $413,075,125 across 381 Biotechnology names. ANAB ranks #89 (0.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | REGN |
Regeneron Pharmaceuticals, Inc.
|
30,522 | $19,031,687 | |
| 2 | ASND |
Ascendis Pharma A/S
|
43,289 | $11,546,042 | |
| 3 | BBIO |
BridgeBio Pharma, Inc.
|
116,611 | $8,685,187 | |
| 4 | MRNA |
Moderna, Inc.
|
123,281 | $8,633,368 | |
| 5 | JAZZ |
Jazz Pharmaceuticals plc
|
30,496 | $7,348,621 | |
| 6 | KYMR |
Kymera Therapeutics, Inc.
|
61,501 | $7,052,319 | |
| 7 | CYTK |
Cytokinetics Inc
|
80,743 | $6,878,496 | |
| 8 | PTCT |
Ptc Therapeutics, Inc.
|
81,923 | $6,682,459 |
All Filings in ANAB
Export CSV
10 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,445,242 | 21,411 | Shares | Defined | 2026-08-14 | |
| 2026-03-31 | $2,802,779 | 50,537 | Shares | Defined | 2026-05-15 | |
| 2025-12-31 | $1,873,121 | 38,637 | Shares | Defined | 2026-02-17 | |
| 2025-09-30 | $554,557 | 18,111 | Shares | Defined | 2025-11-14 | |
| 2025-06-30 | $680,252 | 30,642 | Shares | Defined | 2025-08-12 | |
| 2024-12-31 | $529,774 | 40,013 | Shares | Defined | 2025-02-13 | |
| 2024-09-30 | $679,579 | 20,286 | Shares | Defined | 2024-11-14 | |
| 2024-06-30 | $340,891 | 13,603 | Shares | Defined | 2024-08-12 | |
| 2024-03-31 | $353,653 | 15,704 | Shares | Defined | 2024-05-13 | |
| 2023-12-31 | $228,787 | 10,681 | Shares | Defined | 2024-02-13 | |
| No filing history on record for this holder in this stock. | ||||||